Emerging treatments

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Ri M et al. Intern Med. 2017 Dec 8. doi: 10.2169/internalmedicine.9567-17. [Epub ahead of print]. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Meyers DE et al. Blood Cancer J. 2017 Dec 5;7(12):640. doi: 10.1038/s41408-017-0020-0.…

Diagnostic techniques and prognostic indicators

Functional Imaging with 18F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma Patient. Sachpekidis C et al. Diagnostics (Basel). 2017 Dec 15;7(4). pii: E61. doi: 10.3390/diagnostics7040061. Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Tu…

Current treatments

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. Mateos MV et al. N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1714678. [Epub ahead of print]. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Auner HW et al. Haematologica. 2017…

Complications of myeloma and its treatments

Gastric submucosal haematoma caused by an amyloidoma in the setting of multiple myeloma. Pak SC et al. Arab J Gastroenterol. 2017 Dec 14. pii: S1687-1979(17)30116-8. doi: 10.1016/j.ajg.2017.12.002. [Epub ahead of print]. A case of Multiple Myeloma presenting with diffuse osteosclerosis and multiple bone infarcts. Vignon M et al. Joint Bone Spine. 2017 Dec 9. pii: S1297-319X(17)30203-8. doi: 10.1016/j.jbspin.2017.11.013. [Epub ahead of print]. Systolic dysfunction associated…

Biology and genetics

DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells. Tang H et al. Leuk Lymphoma. 2017 Dec 18:1-7. doi: 10.1080/10428194.2017.1413188. [Epub ahead of print]. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Zhou L et al. Br J Cancer. 2017 Dec 14. doi: 10.1038/bjc.2017.432. [Epub ahead of print]. Jagged1-induced Notch activation contributes to…

Related conditions

Successful Autologous Hematopoietic Stem Cell Transplantation Followed by Bortezomib Maintenance in a Patient with Relapsed CD138-low MultipleSolitary Plasmacytomas Harboring a 17p Deletion. Kitamura H et al. Intern Med. 2017 Nov 20. doi: 10.2169/internalmedicine.9446-17. [Epub ahead of print]. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic…

General

Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma. Postmus D et al. Oncologist. 2017 Oct 27. pii: theoncologist.2017-0257. doi: 10.1634/theoncologist.2017-0257. [Epub ahead of print]. Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Jimenez-Zepeda VH et al. Leuk Lymphoma. 2017 Nov 21:1-7. doi:…

Emerging treatments

CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies. Green DJ et al.Blood. 2017 Nov 20. pii: blood-2017-09-807610. doi: 10.1182/blood-2017-09-807610. [Epub ahead of print]. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Prabhu VV et al. Cell Cycle. 2017 Nov 20:1-29. doi: 10.1080/15384101.2017.1403689. [Epub ahead of print]. A review discussing elotuzumab…

Diagnostic techniques and prognostic indicators

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Bossuyt X et al.Leukemia. 2017 Nov 20. doi: 10.1038/leu.2017.335. [Epub ahead of print]. Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. Cetin AE et al. Nat Commun. 2017 Nov 20;8(1):1613. doi: 10.1038/s41467-017-01593-2. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma. Dalla Palma B et al. Br J Haematol. 2017 Nov…